Light Horse Therapeutics Enters Into Strategic Collaboration With Novartis
Light Horse Therapeutics Inc., a developer of first-in-class small molecule therapeutics, announced a multi-target collaboration with Novartis to identify and develop potentially first-in-class therapeutics using the biotech’s platform. Under the terms of the agreement, Light Horse will receive a $25 million upfront payment.